Engineered γδ T-cells
US11135245B2 · kind B2 · utility
0Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 17, 2015 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | May 19, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/999
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to engineered γδ T-cell(s) and methods for using the same as a therapeutic with a potent and selective ability to target an antigen of choice. Engineered γδ T-cells of the disclosure are useful in the treatment of various cancers, infectious diseases, and immune disorders. Also disclosed are methods for expanding engineered and non-engineered γδ T-cell(s) populations to therapeutically useful quantities. An engineered γδ T-cell of the disclosure can be a universal donor, and can be administered to a subject with any MHC haplotype.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.